26 jun: DSV, 759 - DSV forlænger ombytningsperiode for Panalpina aktier
26 jun: Indre værdi af SmallCap Danmark A/S er opgjort til 10,4 kr. pr. a..
26-06-2019 08:00:00

Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome

Press release – No. 16 / 2019

Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome

  • Short bowel syndrome (SBS) is a complex chronic and severe condition associated with reduced or complete loss of intestinal function and significant unmet medical need

     

  • ZP7570 is a long-acting peptide therapeutic with dual activity on the GLP-1 and GLP-2 receptors

     

  • Pre-clinical and clinical data suggest that the combined GLP-1 and GLP-2 activity may work synergistically to further improve intestinal function in patients with SBS

Copenhagen, June 26, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the dosing of the first subject in a Phase 1 clinical trial to evaluate the safety and tolerability of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS).

The study is a randomized, double-blind, placebo-controlled, single ascending dose trial in 64 healthy subjects, randomized to ZP7570 or placebo within eight cohorts.

ZP7570, a long-acting, dual GLP-1/GLP-2 peptide therapeutic, is designed to further improve management of SBS and may represent a next level of innovation for helping SBS patients to further realize full potential for intestinal rehabilitation. GLP-2 primarily increases the absorptive capacity of the intestine, whereas GLP-1 is believed to act by reducing gastrointestinal motility, thereby allowing more time for the fluids and nutrition to be absorbed. The properties of ZP7570 may also allow for therapeutic opportunities in other gastrointestinal diseases.

“We are committed to changing the lives of people with short bowel syndrome and see good progress in our Phase 3 clinical trial with glepaglutide, a potential best-in-class long-acting GLP-2 analog for treatment of SBS,” commented Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma. “Initiation of this Phase 1 clinical trial with ZP7570, a dual- GLP-1/GLP-2 acting peptide, marks yet another important milestone in our efforts to bring innovative therapeutics to patients living with SBS.”

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

DK +45 50 60 36 36, US +1 857 777 6060

edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

+45 50 60 37 78

lpm@zealandpharma.com

About Short Bowel Syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
19 aug - 
Mandagens aktier: Plusser i Drilling og Mærsk holdt C25..
19 aug - 
Aktier/middag: Novo og andre defensive trækker C25 i mi..
19 aug - 
Bank om Zealand Pharma: Tid til tage profit hjem - anbe..
Relateret debat
18:49 - 
Lige som ting tager tid, så kan ting gå galt.
18:10 - 
Er hypoglykæmi ikke ved at være på tilbagetog, pga. bed..
16:50 - 
Og hvad er Eli Lilly's recovery-procent efter 15 min.? ..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 aug
ZEAL
Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commer..
4
12:27
ZEAL
Ja, og denn røg ud af diverse TA-trendlinier og blev spået nedad...(det kan selvfølgelig nåes endnu)..
3
11:11
ZEAL
Sjovt som man kan tage fejl .. igår anbefalede man at tage gevinst hjem på denne side under nyheder ..
3
17 aug
ZEAL
Du har helt ret alt skal tages i betragtning også de negative kursmål.Her er konsensus pt.:https://w..
3
17 aug
ZEAL
Tror på 300-350 som kursmål fra fx DB inden 12 mdr.
2
15 aug
ZEAL
Pænt kvartal og mange spørgsmål fra analytikerne ved præsentationen.
2
18:10
ZEAL
Er hypoglykæmi ikke ved at være på tilbagetog, pga. bedre diabetes medicin år for år?   Hypopal er v..
1
17 aug
ZEAL
Jeg aner ikke en dyt om, hvor aktien skal hen, alt afhænger af Deres produkter, går alt efter bogen..
1
17 aug
ZEAL
Det et noget et spring, yderlighederne bund i 92 top i 185 ;)   Sådan en gardering kan jeg nok også ..
1
17 aug
ZEAL
Handelsbanken anbefaler at sælge:   Zealand Pharma rapporterede den 15. august et godkendt regnskab ..
1

Verdens næststørste hedgefund indleder shortposition på Chr. Hansen-aktien

20-08-2019 15:02:12
Den amerikanske hedgefond AQR Capital Management satser på kursfald i Chr. Hansen-aktien.Hedgefonden har nu et shortposition på 0,50 pct. af aktierne i Chr. Hansen, fremgår det af en meddelelse tirsdag fra Finanstilsynet.Det er ifølge tilsynet første gang, at den amerikanske hedgefond holder 0,50 pct. eller derover af aktierne i Chr. Hansen.Shorting er spekulation i kursfald. Det sker, ved at en i..

Aktier/middag: Pandora topper C25 mens Jyske Bank bliver sendt ned

20-08-2019 11:46:15
Pandora topper det danske eliteindeks, C25, tirsdag omkring middagstid efter et bedre end ventet regnskab, mens Jyske Bank roder rundt i bunden af indekset efter et noget mere skuffende regnskab.Samlet bevæger C25-indekset sig op med 0,04 pct. til 1124,19. Det sker samtidig med historier om, at Tyskland måske er klar til at indføre finanspolitiske stimuli, samt at der sker positive skridt i forhol..

Aktier/åbning: Pandora trækker C25 op efter blandede regnskabsbolsjer

20-08-2019 09:19:50
Pandora bliver tirsdag morgen sendt til vejrs efter et blandet regnskab for andet kvartal - og kort før smykkeselskabet relancerer sit brand i slutningen af august.Det sker på en dag, hvor regnskaber generelt fylder meget på det danske marked - med netop Pandora som hovedrolleindehaver sammen med blandt andet Jyske Bank og Alm. Brand.Udsvingene er ellers generelt ikke store på tirsdagens marked, o..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Pandora og Jyske til vigtig eksamen i neutralt marked
2
Kapitalfond lukker kæmpe kortposition i DSV efter Panalpina-køb
3
Alm. Brand ramt af renterne: "Et næsten utænkeligt niveauskifte"
4
Aktier/middag: Pandora topper C25 mens Jyske Bank bliver sendt ned
5
Ørsted/UBS: Går fra varm til lunken

Relaterede aktiekurser

Zealand Pharma A/S 146,30 3,4% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 146,30 3,4% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. august 2019 19:21:51
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-20 19:21:51 - 2019-08-20 19:21:51 - 1 - Website: OKAY